Wedbush raised the firm’s price target on Oruka Therapeutics (ORKA) to $45 from $42 and keeps an Outperform rating on the shares. The firm notes ORKA-002 achieved a half-life of 75-80 days, supporting Q6M dosing in psoriasis and Q3M dosing in hidradenitis suppurativa. Safety remained favorable with no reports of IBD or Candida infections despite SAD doses as high as 640 mg; Bimzelx is dosed at 320 mg Q4W for psoriasis, or Q2W for HS during loading.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics price target raised to $71 from $46 at Clear Street
- Oruka Therapeutics: Long-Acting IL-17 Platform Drives Upgraded Valuation and Buy Rating
- Oruka provides updates on Phase 1 trial of ORKA-002, EVERLAST-B ORKA-001 trial
- Oruka Therapeutics initiated with a Buy at UBS
- ORKA-001 Psoriasis Trial: Fresh Phase 2 Update and What It Means for Investors